Memorial Sloan Kettering Cancer Center presents:

Innovations in Personalized Oncology
A CASE-BASED APPROACH

May 4, 2018
Zuckerman Research Center
417 East 68th Street
New York, NY
Innovations in Personalized Oncology

Research advances are leading at an unprecedented rate to opportunities for greater personalization of management approaches for patients with cancer and the promise of related improvements in disease-control and patient-reported outcomes. A challenge facing clinical practitioners, oncology care teams and healthcare systems is the identification and timely integration of these important innovations, often developed at specialty centers, into day-to-day clinical practice in the community setting and closer to where patients live.

A central goal of this CME course is to help busy oncologists and other oncology care team members acquire clinically-relevant, cutting-edge knowledge and translate these innovations into best practices, using lessons learned within the MSK Cancer Alliance and highlighting the personalized approach to cancer care taken by MSK and its Alliance Members.

A CASE-BASED APPROACH
Incorporating a case-based format that utilizes real-life, clinical scenarios, the moderator of each multidisciplinary expert panel will use audience response to examine key decision points and guide targeted commentary and presentations from panel members that include oncologists and other oncology care team members.

Panels will cover eight different diseases, both rare and more common, and address a spectrum of management issues across the care continuum. Immunotherapy, from evolving predictors of response to symptom management for these new agents, will be the focus of two keynote talks.

After this course, attendees will be better able to tailor care to meet the unique needs of their patients and appreciate the role of dynamic partnerships among providers to optimally personalize and improve outcomes of cancer care.

TARGET AUDIENCE
The target audience for this course includes physicians, advanced practice providers, nurses, allied health professionals and administrators looking for innovative, disease-specific oncology content set within multidisciplinary case discussions.

3rd ANNUAL MSK CANCER ALLIANCE SYMPOSIUM
The MSK Cancer Alliance is a collaborative relationship, leveraging bi-directional learning for mutual improvement. It is composed of MSK and a small number of high-quality, community healthcare systems seeking to be centers of excellence in their respective communities with a focus on clinical research and a culture of improvement. The MSK Cancer Alliance strives to bridge the knowledge gaps between an academic comprehensive cancer center such as MSK and community hospitals in order to help facilitate the delivery of high-quality cancer care at the community level, an important need since most cancer care is delivered in the community setting.

Discounted Rate for MSK Alliance Members
MSK offers a discounted rate to all MSK Alliance members to attend a CME course. Please contact cme@mskcc.org for more information or a promotion code.

Please note: Providers outside of the MSK Cancer Alliance are encouraged to attend this symposium.
Symposium Faculty

COURSE DIRECTOR

David G. Pfister, MD
Associate Deputy Physician-in-Chief, Strategic Partnerships
Chief, Head and Neck Oncology
Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center

COURSE CO-DIRECTORS

Steven Jon Shichman, MD
Physician in Chief
Tailwood Urology and Kidney Institute
Hartford Healthcare Cancer Institute

Usman Shah, MD
Assistant Medical Director
Lehigh Valley Health Network Cancer Institute

Starr Mautner, MD
Breast Surgical Oncologist
Miami Cancer Institute

MSK FACULTY

Smita Banerjee, PhD
Assistant Attending Behavioral Scientist
Department of Psychiatry & Behavioral Services

Connie Batlevi, MD, PhD
Assistant Attending Physician
Lymphoma Service
Department of Medicine

Kevin C. De Braganca, MD
Associate Program Director
Pediatric Neuro-Oncology Fellowship
Assistant Attending Pediatrician
Pediatric Neuro-Oncology Service
Department of Pediatrics

Timothy Chan, MD, PhD
Vice Chair, Department of Radiation Oncology
Director, Translational Oncology Division
Director, Immunogenomics and Precision Oncology Platform
PainWebber Chair in Cancer Genetics
Member, Human Oncology & Pathogenesis Program
Attending Physician
Department of Radiation Oncology

Jason Carter, PA-C
Physician Assistant, Clinical Research
Department of Medicine

Andrea Cercek, MD
Assistant Attending Physician
Gastrointestinal Oncology Service
Department of Medicine

Lawrence Dauer, PhD
Clinical Physicist, Radiation Safety Manager
Chair, Emergency Management Committee
Radiochemistry and Imaging Sciences Service
Department of Medical Physics
Department of Radiology

James Eastham, MD
Chief, Urology Service
Peter T. Scardino Chair in Oncology
Attending Surgeon
Department of Surgery

Lauren Evans, MSN, OCN, CCRP
Clinical Trials Nurse Coordinator
Department of Nursing

Ginger Gardner, MD
Physician Lead
Alliance Gynecology Disease Management Team
Associate Attending Physician
Gynecology Service
Department of Surgery

Ruth-Ann Gordon, MSN, FNP-BC, OCN
Clinical Trials Nurse Coordinator
Department of Nursing

INVITED FACULTY

Mario Katigbak, MD
Division Chief of Thoracic Surgery
Hartford Healthcare

Peter Yu, MD
Physician-in-Chief
Hartford HealthCare Cancer Institute

Martin Martino, MD
Medical Director
Minimally Invasive Robotic Surgery
Lehigh Valley Health Network

Paul Sabbatini, MD
Deputy Physician-in-Chief, Clinical Research
Attending Physician
Gynecologic Medical Oncology Service
Department of Medicine

Mona Sabra, MD
Attending Physician
Endocrinology Service
Department of Medicine

Leonard B. Saltz, MD
Executive Director, Clinical Value and Sustainability
Attending Physician
Gastrointestinal Oncology Service
Department of Medicine

Stephen Sands, PsyD
Director, Pediatric Neuropsychology
Attending Psychologist
Psychiatry Service
Department of Pediatrics

Jesse Joshua Smith, MD, PhD
Assistant Attending Surgeon
Colorectal Service
Department of Surgery

William P. Tew, MD
Associate Attending Physician
Gynecologic Medical Oncology Service
Department of Medicine

John Timoney, Pharm D
Assistant Director, Pharmacy
MSKCC, Basking Ridge

Tiffany A. Traina, MD
Associate Attending Physician
Breast Medicine Service
Department of Medicine

Suzanne L. Wolden, MD
Attending Radiation Oncologist
Radiation Oncology Director, Alliance Programs
External Beam Radiotherapy Service
Brachytherapy Service
Department of Radiation Oncology

Rona D. Yaeger, MD
Assistant Attending Physician
Gastrointestinal Oncology Service
Department of Medicine

Helena A. Yu, MD
Assistant Attending Physician
Thoracic Oncology Service
Department of Medicine

Andrew D. Zelenetz, MD, PhD
Medical Director, Quality Informatics
Attending Physician
Lymphoma Service
Division of Hematologic Oncology
Department of Medicine

John S. Park, MD
Associate Program Director, LVHN Colorectal Surgery Fellowship
Lehigh Valley Health Network

Marcio Fagundes, MD
Attending Radiation Oncologist
Miami Cancer Institute

Matthew Hall, MD
Attending Radiation Oncologist
Miami Cancer Institute
**Scientific Agenda**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Moderator(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 AM</td>
<td>Breakfast &amp; Registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td><strong>Opening Remarks</strong></td>
<td>David G. Pfister, MD</td>
<td></td>
</tr>
<tr>
<td>8:10 AM</td>
<td><strong>Keynote Speaker</strong> Evolving Predictors of Response for Immunotherapy</td>
<td>Timothy Chan, MD</td>
<td></td>
</tr>
<tr>
<td>8:35 AM</td>
<td><strong>Non-Hodgkin’s Lymphoma</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CASE PRESENTATION:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>56-year-old Female with a Biopsy-proven Composite of Dominant Follicular Lymphoma, Grade 1-2, and a Component of SLL/CLL</td>
<td>Andrew Zelenetz, MD, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dramatic Response to Mocetinostat in a PT with a CREBP/EP300 Mutation</td>
<td>Connie Ballevi, MD, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Is Observation Still an Appropriate Option for Treatment of Indolent Lymphoma?</td>
<td>Andrew Zelenetz, MD, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Checkpoint Inhibitors in Primary Mediastinal Large Cell Lymphoma</td>
<td>Alison J. Moskowitz, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>APP Role in the Conduct of Phase I Trial of a Novel PI3K Inhibitor</td>
<td>Jason Carter, PA-C</td>
<td></td>
</tr>
<tr>
<td>9:20 AM</td>
<td><strong>Prostate Cancer</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CASE PRESENTATION:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>65-year-old Male with Back Pain, Elevated PSA and Extensively Positive Bone Scan</td>
<td>Philip Kantoff, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treatment vs. Active Surveillance for Good Risk Prostate Cancer: Available Tests, their Performance</td>
<td>James Eastham, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Approach to a Patient with High-risk Localized Prostate Cancer</td>
<td>Sean McBride, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Approach to a Patient with Metastatic Hormone-sensitive Prostate Cancer: What Data Shows Us?</td>
<td>Michael Morris, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>How to Use Genetic Data to Generate a Rational Approach for Patients with Metastatic Castration-resistant Prostate Cancer</td>
<td>Philip Kantoff, MD</td>
<td></td>
</tr>
<tr>
<td>10:05 AM</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 AM</td>
<td><strong>Pediatric Cancers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CASE PRESENTATION:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>18-year-old Female with Desmoplastic Medulloblastoma</td>
<td>Suzanne Walden, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Molecular Subtyping of Medulloblastoma</td>
<td>Marc Rosenblum, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chemotherapy Strategy; Outcomes for Adults</td>
<td>Kevin C. De Braganca, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Role of Proton Craniospinal RT</td>
<td>Matthew Hall, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Long-term Neuropsychiatric Outcomes in Survivors of Medulloblastoma</td>
<td>Stephen Sands, PsyD</td>
<td></td>
</tr>
<tr>
<td>11:15 AM</td>
<td><strong>Gynecological Cancers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CASE PRESENTATION:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-year-old with Stage IIC Optimally Debulked Ovarian Cancer, Recurrent</td>
<td>Paul Sabbatini, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IP vs. IV Dose-dense vs. IV Three-Weekly Treatment</td>
<td>William P. Tew, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Resection at Recurrence - When is it Right to Do It?</td>
<td>Ginger Gardner, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Role of Robotic Resection</td>
<td>Martin Martino, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PARP Maintenance for Everyone?</td>
<td>Roisin E. O’Cearbhail, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cold Cap Use to Prevent Hair Loss</td>
<td>Mikel Ross, RN</td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td><strong>Keynote Speaker</strong> Checkpoint Inhibitors - Symptom Assessment and Management from a Nursing Perspective</td>
<td>Ruth-Ann Gordon, MSN, FNP-BC, OCN</td>
<td></td>
</tr>
<tr>
<td>1:25 PM</td>
<td><strong>Thyroid Cancer</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CASE PRESENTATION:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>71-year-old Male with BRAF-mutated PTC with Anaplastic Transformation</td>
<td>Michael Tuttle, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Initial and Dynamic Risk Stratification: Using Tumor Volume Doubling Times and FDG PET to Predict Outcomes in the Setting of Distant Metastases</td>
<td>Mona Sabra, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novel Systemic Therapy Options for RAI Refractory and Anaplastic Thyroid Cancer</td>
<td>Alan Ho, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Understanding Patient and Family Safety Issues That Are Critical to Effective Implementation of an Outpatient RAI Therapy Program</td>
<td>Lawrence Dauer, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Utilizing Treatment Algorithms for the Management of Expected Dermatological Toxicities to Multitargeted Kinase Inhibitors</td>
<td>Lauren Evans, MSN, OCN, CCRP</td>
<td></td>
</tr>
<tr>
<td>2:10 PM</td>
<td><strong>Colorectal Cancer</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CASE PRESENTATION:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>68-year-old Female with Metastatic Colon Cancer, Mismatch-repair Proficient, RAS Wild-type, BRAF V600E-mutated</td>
<td>Leonard Saltz, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Molecular Profiling of Colorectal Cancer: The Impact of MSK IMPACT</td>
<td>Rona D. Yaeger, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Systemic Therapy for Local-regional Disease and Local-regional Therapy for Metastatic Disease</td>
<td>Andrea Cercek, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Operational Aspects of Non-operative Management in Locally Advanced Rectal Cancer</td>
<td>J. Joshua Smith, MD, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ERAS Protocols for Colorectal Cancers</td>
<td>John S. Park, MD</td>
<td></td>
</tr>
<tr>
<td>2:55 PM</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:20 PM</td>
<td><strong>Lung Cancers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CASE PRESENTATION:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>56-year-old Female, Former Smoker with Stage IV Lung Cancer to Brain and Adrenal Gland</td>
<td>Bernard Park, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treatment of Oligometastatic Non-small Cell Lung Cancer</td>
<td>Helena A. Yu, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lung Cancer Stigma</td>
<td>Smita Banerjee, PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Role of Minimally Invasive Surgery in the Multimodality Treatment of Advanced Lung Cancer</td>
<td>Mario Katigbak, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Optimizing Antiemetic Use</td>
<td>John Timoney, PharmD</td>
<td></td>
</tr>
<tr>
<td>4:05 PM</td>
<td><strong>Breast Cancer</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CASE PRESENTATION:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>49-year-old Female with Unknown Family History, History of 1.1 cm Node-negative, High-grade Triple-negative Primary Breast Cancer s/p Lumpectomy and Radiation Therapy; Now with a Contralateral Primary, Also Triple-negative, and Metastatic Disease</td>
<td>Larry Norton, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Breast Cancer Treatment and Parp Inhibitors</td>
<td>Tiffany A. Traina, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MSK RISE Program</td>
<td>Melissa Pilewskie, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Breast Imaging</td>
<td>Elizabeth Morris, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proton Therapy for Breast Cancer</td>
<td>Marcio Fagundes, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patient-reported Outcomes and Survival</td>
<td>Peter Yu, MD</td>
<td></td>
</tr>
<tr>
<td>4:50 PM</td>
<td><strong>Concluding Remarks</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td><strong>Networking Reception</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Join course faculty for a networking reception in the lobby of Zuckerman Research Center immediately following the course from 5:00-6:00 pm.
Registration

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians (MDs, PhDs and DOs)</td>
<td>$250</td>
</tr>
<tr>
<td>Residents, Fellows, Nurses and Other Healthcare Providers</td>
<td>$150</td>
</tr>
<tr>
<td>Industry Professionals**</td>
<td>$440</td>
</tr>
</tbody>
</table>

Register Online: mskcc.org/PersonalizedOncology

Discounted Rate for MSK Alliance Members
MSK offers a discounted rate to all MSK Alliance members to attend a CME course. Please contact cme@mskcc.org for more information or a promotion code.

REGISTRATION DETAILS
Registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary needs.

- 30% Discounted Rate for MSK Alumni: MSK offers a 30% discounted rate to all MSK Alumni and MSK Alliance members to attend a CME course. Please contact cme@mskcc.org for a promotion code or more information.
- MSK Staff Registration: Registration is complimentary for MSK staff. However, you must register online: mskcc.org/PersonalizedOncology

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Memorial Sloan Kettering Cancer Center, Hartford Healthcare Cancer Institute, Lehigh Valley Health Network, and Miami Cancer Institute of Baptist Health South Florida. Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT
MSK designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.00 Medical Knowledge and Practice Assessment MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit

FACULTY DISCLOSURE
It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

*Industry professionals may attend CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

CONFERENCE LOCATION
Memorial Sloan Kettering Cancer Center
Mortimer B. Zuckerman Research Center
417 East 68th Street
New York, NY 10065

ACCOMMODATIONS
If you’ll be traveling to MSK from out of town, we recommend that you plan your overnight stays as soon as possible. To make the planning a little easier, we’ve negotiated special rates and amenities for patients, families, and caregivers at select hotels in Manhattan. For information on hotels in the area of MSK with discounted rates, please visit: mskcc.org/cme.

CONTACT
Memorial Sloan Kettering Cancer Center
Office of Continuing Medical Education
W: mskcc.org/cme
E: cme@mskcc.org

Join the conversation:
#MSKAllianceCME
f /MSKCME
@MSKCME
in MSK CME LinkedIn Group